Arkansas court upholds medical marijuana proposal

September 27, 2012

(AP)—The Arkansas Supreme Court upheld a proposed ballot measure Thursday that, if successful, would make the state the first in the more conservative southern U.S. to legalize medical marijuana.

Justices rejected a challenge by a coalition of conservative groups who wanted to block the measure from a November vote.

The measure would allow patients with qualifying conditions, such as cancer, glaucoma, HIV, AIDS and Alzheimer's disease, to buy marijuana from nonprofit dispensaries with a doctor's recommendation. A provision would allow minors to use it with parental consent.

The proposal acknowledges that marijuana is still illegal under federal law, but opponents argue that it doesn't adequately explain that users could face federal prosecution.

"This is about the first incremental step to legalizing marijuana for recreational use," said coalition member Larry Page, the director of the Arkansas Faith and Ethics Council.

Seventeen states and the District of Columbia have legalized marijuana in some fashion. Massachusetts voters are also expected to vote on the issue this fall, while the North Dakota Supreme Court ruled that a medical marijuana initiative can't appear on that state's ballot.

The Washington-based Marijuana Policy Project has provided most of the funding for the Arkansas campaign, contributing $251,000.

Officials with the group said they stepped in after polling showed strong support for the measure. Group leaders also cited a "symbolic" value in passing a medical marijuana law in the South.

"I think it's a sign that marijuana policy reform is an idea that is coming of age now across the nation, rather than just in the states where we've seen it so far," said Morgan Fox, the group's communications director. "It's really an important moment."

Gov. Mike Beebe, who is opposed to the proposal, told reporters he doesn't believe voters would legalize medical marijuana.

Explore further: Medical marijuana backers seek inroads in South

shares

Related Stories

Medical marijuana backers seek inroads in South

September 3, 2012
(AP)—The home state of the president who didn't inhale has become an unlikely front in the battle over medical marijuana.

US governors seek federal marijuana clearance

December 1, 2011
A pair of US governors have filed a petition asking the US federal government to allow wider use of medical marijuana by authorizing doctors to prescribe it and pharmacies to provide it.

Adolescents in substance abuse treatment report using someone else's medical marijuana

July 31, 2012
A study published in the July 2012 issue of the Journal of the American Academy of Child and Adolescent Psychiatry found that diverted medical marijuana use among adolescents receiving treatment for substance abuse is very ...

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.